Welcome to our dedicated page for EchoIQ news (Ticker: ECHQF), a resource for investors and traders seeking the latest updates and insights on EchoIQ stock.
ECHOIQ LTD reports developments in AI-based medical technology for cardiovascular assessment using echocardiography data. Company news centers on EchoSolv AS, its decision-support software for severe aortic stenosis, including U.S. hospital deployments, FDA-cleared use, clinical data presentations, and adoption within cardiology workflows. Updates also cover EchoSolv HF, a heart-failure detection tool that has completed clinical validation through the Mayo Clinic Platform Validate program, along with healthcare conference participation and U.S. commercialization activity.
Echo IQ (ticker: ECHQF) deployed its AI decision‑support software EchoSolv AS into Mount Sinai Health System in New York on April 30, 2026. The deployment targets automated assessment of severe aortic stenosis and is positioned as a clinical workflow adjunct for echocardiography teams.
Mount Sinai comprises seven hospitals, 400+ outpatient practices and over 3,760 beds; its Fuster Heart Hospital is ranked No. 1 in New York and No. 2 nationally for Cardiology in U.S. News & World Report 2025–26.
Echo IQ (ASX:EIQ) completed an independent clinical validation of its heart failure decision support software EchoSolv HF with the Mayo Clinic Platform using ~17,000 echocardiogram studies.
The model met its primary endpoint, delivering a sensitivity of 99.5% and a specificity of 91.0%. Completion of this validation is described as the final clinical requirement before a planned FDA 510(k) submission, which Echo IQ expects to lodge in the coming weeks. The company plans to leverage its US footprint to drive uptake if FDA clearance is achieved. A webinar is scheduled for 26 November 2025 at 11:00am AEDT.
Echo IQ (ASX:EIQ / OTC:ECHQF) announced that CEO Dustin Haines will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 12:50 p.m. ET at the Lotte New York Palace.
The event will be webcast and is authorised for release by the company's board. Contact details for investor enquiries are provided for Andrew Grover and Six Degrees Investor Relations.
Echo IQ (OTC:ECHQF) highlighted two studies presented at AHA Scientific Sessions 2025 showing gaps in diagnosing and treating severe aortic stenosis (AS) and potential benefits of EchoSolv AS. A 30,878-echocardiogram investigator study found EchoSolv identified severe AS phenotypes more accurately than cardiologists and improved the male:female diagnosis ratio from 2.2:1 to 1.1:1. A separate real-world analysis of 1.18 million echocardiograms from NEDA linked to national health data found only 36% of women and 45% of men with moderate-to-severe AS received intervention and that “watchful waiting” was associated with substantial life-years lost. EchoSolv AS has FDA clearance and is positioned as a decision-support tool to reduce diagnostic delays and improve intervention timing.